share_log

Novavax | SC 13D: Statement of acquisition of beneficial ownership by individuals-Himanshu H. Shah(6.70%),Shah Capital Management(6.66%), etc.

SEC announcement ·  Apr 15 06:28
Summary by Moomoo AI
On April 10, 2024, Shah Capital Management, Inc., Shah Capital Opportunity Fund LP, and Himanshu H. Shah, collectively referred to as the Reporting Persons, filed a Schedule 13D with the United States Securities and Exchange Commission (SEC) regarding their significant investment in Novavax, Inc. The filing indicates that Shah Capital Management, as an investment adviser, and Shah Capital Opportunity Fund LP, a partnership, along with Himanshu H. Shah, President and Chief Investment Officer of Shah Capital, have acquired substantial shares of Novavax. The Reporting Persons collectively own 9,326,176 shares through Shah Capital Management, 8,700,000 shares through Shah Capital Opportunity Fund LP, and 9,383,335 shares by Himanshu H. Shah individually, representing 6.66%, 6.21%, and 6.70% of the outstanding shares, respectively. The shares were acquired for investment purposes in the ordinary...Show More
On April 10, 2024, Shah Capital Management, Inc., Shah Capital Opportunity Fund LP, and Himanshu H. Shah, collectively referred to as the Reporting Persons, filed a Schedule 13D with the United States Securities and Exchange Commission (SEC) regarding their significant investment in Novavax, Inc. The filing indicates that Shah Capital Management, as an investment adviser, and Shah Capital Opportunity Fund LP, a partnership, along with Himanshu H. Shah, President and Chief Investment Officer of Shah Capital, have acquired substantial shares of Novavax. The Reporting Persons collectively own 9,326,176 shares through Shah Capital Management, 8,700,000 shares through Shah Capital Opportunity Fund LP, and 9,383,335 shares by Himanshu H. Shah individually, representing 6.66%, 6.21%, and 6.70% of the outstanding shares, respectively. The shares were acquired for investment purposes in the ordinary course of business, with no current plans to influence or change the company's operations. The Reporting Persons may engage in discussions with Novavax's management or other stakeholders and may alter their investment strategy based on the company's performance and market conditions. The filing also includes a Joint Filing Agreement and a letter to the Board of Directors (BOD Letter) as exhibits.

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more